

## Bibliografía

1. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. *Cancer Immunol Res.* 2014;2:288-94.
2. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. *Biochem J.* 1990;265:621-36.
3. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. *Adv Immunol.* 1993;54:1-78.
4. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, *et al.* Structure and function of a new STAT-induced STAT inhibitor. *Nature.* 1997;387:924-9.
5. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem J.* 2003;374:1-20.
6. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, *et al.* Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. *Cell.* 1989;58:573-81.
7. Oh JW, Revel M, Chebath J. A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. *Cytokine.* 1996;8:401-9.
8. Riethmueller S, Somasundaram P, Ehlers JC, Hung CW, Flynn CM, Lokau J, *et al.* Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation. *PLoS Biol.* 2017;15:e2000080.
9. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. *Cytokine.* 1992;4:96-100.
10. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol.* 2015;16:448-57.
11. Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, *et al.* Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. *Nat Immunol.* 2017;18:74-85.
12. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, *et al.* Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. *Blood.* 1993;82:1120-6.
13. Lamertz L, Rummel F, Polz R, Baran P, Hansen S, Waetzig GH, *et al.* Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses. *Sci Signal.* 2018;11.
14. Murakami M, Kamimura D, Hirano T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. *Immunity.* 2019;50:812-31.
15. Nishida K, Yoshida Y, Itoh M, Fukada T, Ohtani T, Shirogane T, *et al.* Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors. *Blood.* 1999;93:1809-16.
16. Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, *et al.* A gp130-Src-YAP module links inflammation to epithelial regeneration. *Nature.* 2015;519:57-62.
17. Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN, *et al.* Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. *Immunity.* 2012;36:239-50.
18. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. *Cytokine.* 2014;70:11-20.
19. Maeda K, Akira S. Regulation of mRNA stability by CCCH-type zinc-finger proteins in immune cells. *Int Immunol.* 2017;29:149-55.
20. Masuda K, Ripley B, Nishimura R, Mino T, Takeuchi O, Shioi G, *et al.* Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. *Proc Natl Acad Sci U S A.* 2013;110:9409-14.
21. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. *Cell.* 2009;139:693-706.
22. Chou DB, Sworder B, Bouladoux N, Roy CN, Uchida AM, Grigg M, *et al.* Stromal-derived IL-6 alters the balance of myeloerythroid progenitors during *Toxoplasma gondii* infection. *J Leukoc Biol.* 2012;92:123-31.
23. Liu F, Poursine-Laurent J, Wu HY, Link DC. Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. *Blood.* 1997;90:2583-90.
24. Jones S A. Directing transition from innate to acquired immunity: defining a role for IL-6. *J Immunol.* 2005;175:3463-8.
25. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, *et al.* IgG1 plasmacytosis in interleukin 6 transgenic mice. *Proc Natl Acad Sci U S A.* 1989;86:7547-51.
26. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, *et al.* Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature.* 2006;441:235-8.
27. Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, *et al.* A validated regulatory network for Th17 cell specification. *Cell.* 2012;151:289-303.
28. Karnowski A1, Chevrier S, Belz GT, Mount A, Emslie D, D'Costa K, *et al.* B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. *J Exp Med.* 2012;209:2049-64.
29. De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, *et al.* Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. *Arthritis Rheum.* 2006;54:3551-63.

30. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, *et al.* Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. *Arthritis Rheum.* 2003;48:1521-9.
31. Peters M, Blinn G, Jostock T, Schirmacher P, Meyer zum Büschenfelde KH, Galle PR, *et al.* Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. *Gastroenterology.* 2000;119:1663-71.
32. Wolsk E, Mygind H, Grøndahl TS, Pedersen BK, van Hall G. IL-6 selectively stimulates fat metabolism in human skeletal muscle. *Am J Physiol Endocrinol Metab.* 2010;299:E832-40.
33. Febbraio MA, Ott P, Nielsen HB, Steensberg A, Keller C, Krstrup P, *et al.* Hepatosplanchnic clearance of interleukin-6 in humans during exercise. *Am J Physiol Endocrinol Metab.* 2003;285:E397-402.
34. Nakagawa H, Tamura T, Mitsuda Y, Goto Y, Kamiya Y, Kondo T. *et al.* Inverse correlation between serum interleukin-6 and iron levels among Japanese adults: a cross-sectional study. *BMC Hematol.* 2014;14:6.
35. Stenlöf K, Wernstedt I, Fjällman T, Wallenius V, Wallenius K, Jansson JO. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. *J Clin Endocrinol Metab.* 2003;88:4379-83.
36. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. *J Exp Med.* 1989;169:333-8.
37. Fraunberger P, Wang Y, Holler E, Parhofer KG, Nagel D, Walli AK, *et al.* Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever. *Shock.* 2006;26:10-2.
38. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, *et al.* Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. *Nephrol Dial Transplant.* 2004;19:1154-60.
39. Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. *Nat Med.* 2013;19:822-4.
40. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, *et al.* Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. *Eur J Immunol.* 1988;18:1797-801.
41. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. *Ann Rheum Dis.* 1993;52:232-4.
42. Straub RH, Müller-Ladner U, Lichtinger T, Schölmerich J, Menninger H, Lang B. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. *Br J Rheumatol.* 1997;36:1298-303.
43. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, *et al.* Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. *Mod Rheumatol.* 2014;24:17-25.
44. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, *et al.* Interleukin 6 is required for the development of collagen-induced arthritis. *J Exp Med.* 1998;187:461-8.
45. Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, *et al.* Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. *Arthritis Rheum.* 2008;58:3710-9.
46. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, *et al.* Interleukin 6 plays a key role in the development of antigen-induced arthritis. *Proc Natl Acad Sci U S A.* 1998;95:8222-6.
47. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, *et al.* Distinct contribution of IL-6, TNF- $\alpha$ , IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. *J Clin Invest.* 2004;114:582-8.
48. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. *Immunol Today.* 1990;11:443-9.
49. Yoshizaki K, Nakagawa T, Kaieda T, Muraguchi A, Yamamura Y, Kishimoto T. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. *J Immunol.* 1982;128:1296-301.
50. Dienz O, Eaton SM, Bond JP, Neveu W, Moquin D, Noubade R, *et al.* The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. *J Exp Med.* 2009;206:69-78.
51. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, *et al.* Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. *J Bone Miner Res.* 1996;11:88-95.
52. Rincón M, Anguita J, Nakamura T, Fikrig E, Flavell RA. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. *J Exp Med.* 1997;185:461-9.
53. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. *Eur J Immunol.* 2010;40:1830-5.
54. Lee GR. The Balance of Th17 versus Treg Cells in Autoimmunity. *Int J Mol Sci.* 2018;19.
55. Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, *et al.* Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. *Arthritis Rheum.* 2012;64:2499-503.
56. Carbone G, Wilson A, Diehl SA, Bunn J, Cooper SM, Rincon M. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. *Int J Biol Sci.* 2013;9:279-88.

57. Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. *Mod Rheumatol*. 2019;29:258-67.
58. Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. *Arthritis*. 2011;2011:765624.
59. Yoo SA, Kwok SK, Kim WU. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. *Mediators Inflamm*. 2008;2008:129873.
60. Aida Y, Honda K, Tanigawa S, Nakayama G, Matsumura H, Suzuki N, et al. IL-6 and soluble IL-6 receptor stimulate the production of MMPs and their inhibitors via JAK-STAT and ERK-MAPK signalling in human chondrocytes. *Cell Biol Int*. 2012;36:367-76.
61. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. *Rheumatology (Oxford)*. 2008;47:1635-40.
62. Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. *Osteoporos Int*. 2010;21:1287-93.
63. Hashizume M, Tan SL, Takano J, Ohsawa K, Hasada I, Hanasaki A, et al. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights. *Int Rev Immunol*. 2015;34:265-79.
64. Moreland LW, Curtis JR. Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. *Semin Arthritis Rheum*. 2009;39:132-43.
65. Raj DS. Role of interleukin-6 in the anemia of chronic disease. *Semin Arthritis Rheum*. 2009;38:382-8.
66. Sangkhae V, Nemeth E. Regulation of the Iron Homeostatic Hormone Heparin. *Adv Nutr*. 2017;8:126-36.
67. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *J Clin Invest*. 2004;113:1271-6.
68. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. *Blood*. 1989;74:1241-4.
69. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. *Am J Med*. 2008;121:S9-14.
70. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. *Am J Med*. 2008;121:S21-31.
71. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. *Ann Rheum Dis*. 2015;74:694-702.
72. Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2015;17:52.
73. Ozmen M, Yersal O, Ozturk S, Soysal D, Koseoglu MH. Prevalence of the metabolic syndrome in rheumatoid arthritis. *Eur J Rheumatol*. 2014;1:1-4.
74. Desseinh PH, Solomon A, Hollan I. Metabolic abnormalities in patients with inflammatory rheumatic diseases. *Best Pract Res Clin Rheumatol*. 2016;30:901-15.
75. Ferraz-Amaro I, Gonzalez-Juanatey C, Lopez-Mejias R, Riancho-Zarrabeitia L, Gonzalez-Gay MA. Metabolic syndrome in rheumatoid arthritis. *Mediators Inflamm*. 2013;2013:710928.
76. Giles JT, Danielides S, Szklo M, Post WS, Blumenthal RS, Petri M, et al. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. *Arthritis Rheumatol*. 2015;67:626-36.
77. Wojdasiewicz P, Poniatowski LA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. *Mediators Inflamm*. 2014;2014:561459.
78. Rohleder N, Aringer M, Boentert M. Role of interleukin-6 in stress, sleep, and fatigue. *Ann N Y Acad Sci*. 2012;1261:88-96.
79. März P, Cheng JG, Gadiant RA, Patterson PH, Stoyan T, Otten U, et al. Sympathetic neurons can produce and respond to interleukin 6. *Proc Natl Acad Sci U S A*. 1998;95:3251-6.
80. Schaible HG. Nociceptive neurons detect cytokines in arthritis. *Arthritis Res Ther*. 2014;16:470.
81. Zhou YQ, Liu Z, Liu ZH, Chen SP, Li M, Shahveranov A, et al. Interleukin-6: an emerging regulator of pathological pain. *J Neuroinflammation*. 2016;13:141.
82. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA. Impact of fatigue on health-related quality of life in rheumatoid arthritis. *Arthritis Rheum*. 2004;51:578-85.
83. Eijssbouts AM, van den Hoogen FH, Laan RF, Hermus AR, Sweep CG, van de Putte LB. Hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2005;23:658-64.
84. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. *J Clin Endocrinol Metab*. 1993;77:1690-4.
85. Vgontzas AN, Papanicolaou DA, Bixler EO, Loutsikas A, Zachman K, Kales A, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. *J Clin Endocrinol Metab*. 1999;84:2603-7.
86. Sturgeon JA, Finan PH, Zautra AJ. Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways. *Nat Rev Rheumatol*. 2016;12:532-42.
87. Virtanen M, Shipley MJ, Batty GD, Hamer M, Allan CL, Lowe GD, et al. Interleukin-6 as a predictor of symptom resolution in psychological distress: a cohort study. *Psychol Med*. 2015;45:2137-44.
88. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. *Cytokine*. 1997;9:853-8.

89. Bull SJ, Huez-Diaz P, Binder EB, Cubells JF, Ranjith G, Maddock C, *et al.* Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. *Mol Psychiatry*. 2009;14:1095-104.
90. Girotti M, Donegan JJ, Morilak DA. Influence of hypothalamic IL-6/gp130 receptor signaling on the HPA axis response to chronic stress. *Psychoneuroendocrinology*. 2013;38:1158-69.